Monoclonal antibody specific for beta-A4 (1-42) peptide

(19)

(11)

EP 1 160 256 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	01.04.2009 Bulletin 2009/14

(45)	Mention of the grant of the patent:
	27.06.2007 Bulletin 2007/26

(21)	Application number: 01114005.0

(22)	Date of filing: 14.02.1996

(51)

International Patent Classification (IPC):

C07K 16/18^(2006.01)

(54)	Monoclonal antibody specific for beta-A4 (1-42) peptide Für das Beta-A4 (1-42) Peptid spezifischer monoklonaler Antikörper Anticorps monoclonal spécifique du peptide beta-A4 (1-42)

(84)	Designated Contracting States:
	AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

(30)

Priority:

14.02.1995 US 388463

(43)	Date of publication of application:
	05.12.2001 Bulletin 2001/49

(60)	Divisional application:
	07012421.9 / 1842859

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	96906616.6 / 0809656

(73)	Proprietors:
	Wyeth Madison, New Jersey 07940 (US) Elan Pharma International Limited Athlone Westmeath (IE)

(72)	Inventors:
	Konig, Gerhard 40476 Düsseldorf (DE) Graham, Paul New Haven, CT 06511 (US)

(74)	Representative: Mercer, Christopher Paul et al
	Carpmaels & Ransford 43, Bloomsbury Square London WC1A 2RA London WC1A 2RA (GB)

(56)

References cited: :

WO-A-91/16628

WO-A-94/17197

GREER M. MURPHY ET AL.: "DEVELOPMENT OF A MONOCLONAL ANTIBODY SPECIFIC FOR THE COOH-TERMINAL OF BETA-AMYLOID 1-42 AND ITS IMMUNOHISTOCHEMICAL REACTIVITY IN ALZHEIMER'S DISEASE AND RELATED DISORDERS." AMERICAN JOURNAL OF PATHOLOGY, vol. 144, no. 5, May 1994 (1994-05), pages 1082-1088, XP000573948

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).